Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASHYuki Kimura, Kazuaki Chayama, Hideyuki Hyogo et al.|Journal of Gastroenterology|2010Cited by 160
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering propertyHideyuki Hyogo, Kazuaki Chayama, Sho‐ichi Yamagishi et al.|Digestive and Liver Disease|2012Cited by 55
Postprandial insulin secretion pattern is associated with histological severity in non‐alcoholic fatty liver disease patients without prior known diabetes mellitusYuki Kimura, Kazuaki Chayama, Koji Arihiro et al.|Journal of Gastroenterology and Hepatology|2010Cited by 43
Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose toleranceHideyuki Hyogo, Kazuaki Chayama, Sho‐ichi Yamagishi et al.|Digestive and Liver Disease|2012Cited by 9
Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver diseaseHideyuki Hyogo, Kazuaki Chayama, Sho‐ichi Yamagishi et al.|Clinical Biochemistry|2012Cited by 5